Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG--AFU 26 NIVOREN.

The need for biomarker in treatment of advanced RCC remains critical. We investigated the impact of duration exposure to antiangiogenic on clinical outcomes in 354 metastatic ccRCC treated with nivolumab in the NIVOREN-GETUG-AFU26 trial. Nivolumab activity in second line is independent from first-line duration of VEGFR TKI. No difference has been observed in 8 circulating soluble factors measured. Background: In metastatic renal clear cell carcinoma (ccRCC), vascular endothelial growth factor receptor (VEGFR) and immune checkpoint are 2 main therapeutic targets. We investigated the impact of duration exposure to antiangiogenic on immunotherapy clinical outcomes in metastatic ccRCC. Methods: Patients from NIVOREN trial who received nivolumab after only 1 prior antiangiogenic therapy were included. Response rate, clinical benefit, progression free survival (PFS) and overall survival (OS) were prospectively analyzed depending on the duration of the first line (< 6 months, =6 months) and exploratory in patients with long first line exposure (=18 months). The circulating levels of 8 plasma proteins and cytokines at baseline were collected and compared according to first line antiangiogenic duration. Results: Among 354 patients, 127 (36%) and 227 (64%) patients had received first line antiangiogenic for < 6months and = 6months respectively. Respective duration of first line therapy was not associated with objective response to nivolumab (20.5% vs. 23.9%, P = .50), or PFS (HR 0.92; P = .421). Median OS was respectively 16.6 and 31.3 months in the < 6 and =6 months subgroups respectively. Adjusted on international metastatic renal cell carcinoma database consortium risk, age and metastatic site, OS was longer in patients with longer treatment duration in the first line setting (HR 0.73; P = .017). Duration of first line VEGFR TKI was independent from circulating levels of 8 proteins and cytokines at nivolumab baseline. Conclusion: Nivolumab activity in second line is independent from first-line duration of VEGFR TKI. However, first line VEGFR TKI duration = 6 months is associated with longer OS. [ABSTRACT FROM AUTHOR]